Monsanto Will Profit Most From Bed Bug Epidemic, Poll Says
NEW YORK (TheStreet) -- According to readers of TheStreet, the company most likely to benefit from the bed-bug epidemic is agricultural seed giant Monsanto (MON) -- which also happens to be one the biggest names in the business of manufacturing pest control products.
While Monsanto garnered 21.7% of the votes in our poll on which stock is best poised to profit from the bed-bug outbreak, Sealy (ZZ) came in a close second, receiving 20.4% of the votes cast. Clorox (CLX) came in third, with 15.3% of the votes.
E.I. du Pont de Nemours (DD) picked up 14% of the votes, while Procter & Gamble (PG) received 12.1%. Rollins (ROL), Ecolab (ECL) and Bayer AG (BAYRY) logged 7.6%, 5.1% and 3.8% respectively.
According to brand and communications company Hall & Partners, its WebWord tool -- which the company uses to monitor online "buzz" for clients and brands it's tracking -- shows that "fail" and "resistant" are among the words most strongly associated with searches on "bed bugs and cure." However, no brand is being singled as a failure. Likewise, no search results were showing up for "cure."
Hall & Partners believes these results indicate an important opportunity for many consumer goods companies. "While people are talking a lot about bed bugs lately, no one seems to know what to do with them," Hall & Partners director Brigette Lytle said. "If a brand started talking about how they are a cure for bed bugs, they can have a stronghold in the market before anyone else gets out there with it." According to reports, the bed-bug outbreak has reached record levels across the U.S., with Google's (GOOG) New York City office being among the latest to fall victim to the critters. -- Written by Andrea Tse in New York.>To contact the writer of this article, click here: Andrea Tse. >To follow the writer on Twitter, go to Andrea Tse. >To submit a news tip, send an email to: tips@thestreet.com.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
